Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-na ïve HIV-1 infected adults.

CONCLUSION: RPV is effective, safe and considerably more tolerable than compared to NNRTI or boosted PI in ABC/3TC-containing regimens for treatment-naïve patients. It offers an affordable and attractive option, especially in resource-limited settings. PMID: 32438914 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32438914?dopt=Abstract

Source: AIDS Research and Therapy - May 20, 2020 Category: Infectious Diseases Authors: Ho S, Wong JG, Ng OT, Lee CC, Leo YS, Lye DCB, Wong CS Tags: AIDS Res Ther Source Type: research